Sotagliflozin, an FDA-approved drug for type 2 diabetes and kidney disease, significantly reduces heart attack and stroke risk, according to an international trial. Unlike other SGLT2 inhibitors, it … [+4545 chars]
New FDA-Approved Diabetes Drug Slashes Heart Attack and Stroke Risk - SciTechDaily
Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a recently FDA-approved drug for treating type 2 diabetes and k…
Source:SciTechDaily
Published:
Related News
RFK Jr. Is Waging a War on Women - Slate
And on moms in particular.
Slate Magazine•Shannon Palus
A doctor says all it takes is a “few intentional minutes a day” to improve balance and reduce your risk of falls - Fit&Well
Three drills that take just a few minutes a day
Fitandwell.com•Maddy Biddulph
Ausländer by Michael Moritz — a Holocaust story with echoes in the present - Financial Times
A powerful family memoir sounds a warning from history about antisemitism and threats to democracy
Financial Times•Richard Waters